RT info:eu-repo/semantics/article
T1 Prediction of poor outcome in clostridioides difficile infection: A multicentre external validation of the toxin B amplification cycle
A1 Reigadas, E.
A1 Alcalá, L.
A1 Marín, M.
A1 Martin, A.
A1 Muñoz, P.
A1 Eiros Bouza, José María
A1 Sánchez Arroyo, Rafael J.
A1 Azcona Gutiérrez, José Manuel
A1 García García, Concepción
A1 Fernández Caso, Belén
A1 García Blanco, Alicia
A1 Fernandez Pittol, Mariana
A1 Álvarez Martínez, Míriam José
A1 Orellana Miguel, M. Ángeles
A1 Nuño, Enrique Muñoz
A1 Álvarez Paredes, Ledicia
A1 Megías, Gregoria
A1 López Medrano, Ramiro
A1 Foz, Carlos Fuster
A1 Leiva, José
A1 Fernández-Alonso, Mirian
A1 Vega, Silvia
A1 Hernando, Susana
A1 Frutos, Mónica de
A1 Trujillo, Gloria
A1 López, Joan
A1 Molina de Diego, Araceli N.
A1 López Hontangas, José Luis
A1 Guerrero Vadillo, María
K1 Infección por clostridioides difficile
K1 Reaparición
K1 Predictores
K1 Ciclo de amplificación
K1 Cuantificación de toxina b
K1 2420 Virología
AB Classification of patients according to their risk of poor outcomes in Clostridioides difficile infection (CDI) would enable implementation of costly new treatment options in a subset of patients at higher risk of poor outcome. In a previous study, we found that low toxin B amplification cycle thresholds (Ct) were independently associated with poor outcome CDI. Our objective was to perform a multicentre external validation of a PCR-toxin B Ct as a marker of poor outcome CDI. We carried out a multicentre study (14 hospitals) in which the characteristics and outcome of patients with CDI were evaluated. A subanalysis of the results of the amplification curve of real-time PCR gene toxin B (XpertTM C. difficile) was performed. A total of 223 patients were included. The median age was 73.0 years, 50.2% were female, and the median Charlson index was 3.0. The comparison of poor outcome and non–poor outcome CDI episodes revealed, respectively, the following results: median age (years), 77.0 vs 72.0 (p = 0.009); patients from nursing homes, 24.4% vs 10.8% (p = 0.039); median leukocytes (cells/μl), 10,740.0 vs 8795.0 (p = 0.026); and median PCR-toxin B Ct, 23.3 vs 25.4 (p = 0.004). Multivariate analysis showed that a PCR-toxin B Ct cut-off <23.5 was significantly and independently associated with poor outcome CDI (p = 0.002; OR, 3.371; 95%CI, 1.565–7.264). This variable correctly classified 68.5% of patients. The use of this microbiological marker could facilitate early selection of patients who are at higher risk of poor outcome and are more likely to benefit from newer and more costly therapeutic options.
PB Elsevier
SN 1075-9964
YR 2020
FD 2020
LK http://uvadoc.uva.es/handle/10324/42918
UL http://uvadoc.uva.es/handle/10324/42918
LA eng
NO Anaerobe, 2020, vol. 61,  102079
NO Producción Científica
DS UVaDOC
RD 23-dic-2024